Antaros Medical AB   Report issue

For profit Phase 1 Phase 4
Founded: Uppsala Sweden (2014)

Organization Overview

First Clinical Trial
2015
NCT02426541
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Antaros Medical | Antaros Medical AB

Active Ingredients

Drugs in Phase 4 Trials (4)

dapagliflozin (farxiga) (1 trial)

exenatide (byetta) (1 trial)

glucagon (1 trial)

sodium chloride (1 trial)

Drugs in Phase 1 Trials (3)

ga-do3a-vs-cys40-tuna-2 (1 trial)

lactic acid (1 trial)

sar425899 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Insulin Resistance (Phase 4)

Overweight (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 7